↓ Skip to main content

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system

Overview of attention for article published in Frontiers in Pharmacology, September 2023
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
7 Mendeley